GLP-3 RT (RETATRUTIDE) Description: GLP-3 RT (Retatrutide) is an investigational unimolecular triple agonist of the glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR)
Week 1-2 The typical dosing used in trials is 1 mg/week for the entirety, or 2 or 4 mg/week for 4 weeks and then staying on 4 mg/week for the rest of the trial, or titrating up to 8 or 12 mg/week
Role of GLP-1, GIP, and Glucagon GLP-1 agonists, like Retatrutide, work on the GLP-1 receptor to boost insulin and slow down glucagon
doi: 10.1038/nrendo.2015.231
The FDA then takes about 60 days to decide whether to accept the filing, and review after acceptance is typically 610 months (priority vs standard)
Could They Be Studied Together